- Home
- EE vs VIR Comparison
EE vs VIR Comparison
Compare EE & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EE
- VIR
- Stock Information
- Founded
- EE 2003
- VIR 2016
- Country
- EE United States
- VIR United States
- Employees
- EE N/A
- VIR N/A
- Industry
- EE Oil/Gas Transmission
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- EE Utilities
- VIR Health Care
- Exchange
- EE Nasdaq
- VIR Nasdaq
- Market Cap
- EE 825.4M
- VIR 724.1M
- IPO Year
- EE 2022
- VIR 2019
- Fundamental
- Price
- EE $26.00
- VIR $5.97
- Analyst Decision
- EE Hold
- VIR Strong Buy
- Analyst Count
- EE 6
- VIR 7
- Target Price
- EE $31.17
- VIR $33.57
- AVG Volume (30 Days)
- EE 835.2K
- VIR 1.2M
- Earning Date
- EE 05-07-2025
- VIR 05-01-2025
- Dividend Yield
- EE 0.93%
- VIR N/A
- EPS Growth
- EE 13.91
- VIR N/A
- EPS
- EE 1.27
- VIR N/A
- Revenue
- EE $851,437,000.00
- VIR $74,205,000.00
- Revenue This Year
- EE $4.96
- VIR N/A
- Revenue Next Year
- EE $32.16
- VIR $17.69
- P/E Ratio
- EE $20.39
- VIR N/A
- Revenue Growth
- EE N/A
- VIR N/A
- 52 Week Low
- EE $16.39
- VIR $4.95
- 52 Week High
- EE $32.99
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- EE 42.69
- VIR 45.21
- Support Level
- EE $24.00
- VIR $5.32
- Resistance Level
- EE $26.75
- VIR $5.86
- Average True Range (ATR)
- EE 1.30
- VIR 0.43
- MACD
- EE 0.07
- VIR 0.12
- Stochastic Oscillator
- EE 70.42
- VIR 78.83
About EE Excelerate Energy Inc.
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.